BRAF and colorectal carcinoma: Hence, molecular genomic services for CRC in LMICs represents a significant unmet clinical need and analysis of molecular markers such as MMR, and BRAF (either by molecular analysis or by mutation-specific immunohistochemistry) could improve the quality of health care provided in this setting5,10.